Skip to main content
SpringerLink
Log in

The reversal of multidrug resistance

  • Chapter
Concepts, Mechanisms, and New Targets for Chemotherapy

Part of the book series: Cancer Treatment and Research ((CTAR,volume 78))

Abstract

The failure of chemotherapy to achieve complete and durable responses has been attributed in large part to the phenomenon of drug resistance. In the laboratory, tumor cells can be selected for resistance to a particular cytotoxin by repeated exposure to that drug. The selected cells often display crossresistance to a number of functionally and structurally distinct drugs. This drug-resistant phenotype is referred to as multidrug resistance (MDR). Currently, the best understood mechanism of multidrug resistance is that which is mediated by the mdr 1 gene product, P-glycoprotein (P-gp). P-gp is a plasma membrane protein that functions as a multidrug transporter capable of effluxing a variety of antineoplastic agents, predominantly those derived from natural products (see tables 3-1). Cells which express P-gp accumulate less cytotoxin and, hence, are resistant to these drugs [1–6].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Roninson IB. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press: New York and London, 1991.

    Google Scholar 

  2. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60:157–180, 1993.

    PubMed  CAS  Google Scholar 

  3. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol 12:243–253, 1992.

    PubMed  CAS  Google Scholar 

  4. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 81(9):2215–2222, 1993.

    PubMed  CAS  Google Scholar 

  5. Nooter K, Herwijer H. Multidrug resistance (MDR) in human cancers. Br J Cancerm 63:663–669, 1991.

    CAS  Google Scholar 

  6. Ling V. P-glycoprotein and resistance to anticancer drugs. Cancer 69:2603–2609, 1992.

    PubMed  CAS  Google Scholar 

  7. Coley HM, Twentyman PR, Workman P. The efflux of anthracyclines in multidrugresistant cell lines. Biochem Pharmacol 46(8):1317–1326, 1993.

    PubMed  CAS  Google Scholar 

  8. Vasey PA, Bissett D, Kaye SB, Cassidy J. Clinical phase I study of methoxymorphinyl-doxorubicin (FCE 23762). Proc Am Assoc Cancer Res 35:399, 1994.

    Google Scholar 

  9. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A, Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 7:572–579, 1993.

    PubMed  CAS  Google Scholar 

  10. Lai GM, Chen YN, Mickley LA. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:696–703, 1991.

    PubMed  CAS  Google Scholar 

  11. Lang A, Köberle D, Lehnert M. Effects of exposure time on degree of drug resistance and chemosensitizer activity in P-glycoprotein-positive tumor cell lines. Ann Oncol 5(5):155, 1994.

    Google Scholar 

  12. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol 11(8):1573–1582, 1993.

    PubMed  CAS  Google Scholar 

  13. Wilson WH, Berg S, Kang Y, et al. Phase I/II study of taxol 96-hour infusion in refractory lymphoma and breast cancer: pharmacodynamics and analysis of multi-drug resistance (mdr-1). Proc Am Soc Clin Oncol 12:134, 1993.

    Google Scholar 

  14. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972, 1981.

    PubMed  CAS  Google Scholar 

  15. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and Adriamycin in human hematopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43:2267–2272, 1983.

    PubMed  CAS  Google Scholar 

  16. Schuurhuis G, Broxterman H, van der Hoeven J, Pinedo H, Lakelma J. Potentiation of doxorubicin cytotoxicity by calcium antagonist bepridil in anthracycline-resistant and sensitive cell lines. Cancer Chemother Pharmacol 20:285–290, 1987.

    PubMed  CAS  Google Scholar 

  17. Chauffert B, Martin M, Hammann A, Michel M, Martin F. Amiodarone-induced enhancement of doxorubicin and 4-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res 46:825–830, 1986.

    PubMed  CAS  Google Scholar 

  18. Damle BD, Sridhar R, Desai P. Dipyridamole modulates multidrug resistance and intracellular as well as nuclear levels of doxorubicin in B16 melanoma cells. Int J Cancer 56:113–118, 1994.

    PubMed  CAS  Google Scholar 

  19. Stallard S, Kaye SB. Reversal of resistance in the breast cancer cell-line MCF-7/Adr® was most effective with the modulating agent quinidine. Br J Cancer 60:500, 1989.

    Google Scholar 

  20. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye S. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28(1): 28–31, 1992.

    PubMed  CAS  Google Scholar 

  21. Chauffert B, Pelletier H, Corda C. Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Br J Cancer 62:395–397, 1990.

    PubMed  CAS  Google Scholar 

  22. Inaba M, Maruyama E. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with special emphasis on quinacrine. Cancer Res 48:2064–2067, 1988.

    PubMed  CAS  Google Scholar 

  23. Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp O, Petit JM, Martin F, Chauffert B. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 52:2797–2801, 1992.

    PubMed  CAS  Google Scholar 

  24. Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res 49:6901–6905, 1989.

    PubMed  CAS  Google Scholar 

  25. Hofgli E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin-D and doxorubicin in multidrug-resistant cells. Int J Cancer 44:149–154, 1989.

    Google Scholar 

  26. Kirk J, Houlbrook S, Stuart NSA, Stratford IJ, Harris AL, Carmichael J. Different modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67(6):1189–1195, 1993.

    PubMed  CAS  Google Scholar 

  27. DeGregorio M, Ford J, Benz C, Wiebe V. Toremifene: pharmacology and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359–1364, 1989.

    Google Scholar 

  28. Fleming GF, Amato JM, Agresti M, Safa AR. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 29:445–449, 1991.

    Google Scholar 

  29. Twentyman PR, Bleehen NM. Resistance in modification by PSC-833, a novel nonimmunosuppressive cyclosporin A. Eur J Cancer 27(12):1639–1642, 1991.

    PubMed  CAS  Google Scholar 

  30. Ford J, Bruggeman E, Pastan I, Gottesman M, Hait W. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756, 1990.

    PubMed  CAS  Google Scholar 

  31. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chien Reiss M. Terfenadine (Seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 45(2):401–406, 1993.

    PubMed  CAS  Google Scholar 

  32. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85(20): 1685–1690, 1993.

    PubMed  CAS  Google Scholar 

  33. Mazzanti R, Croop JM, Gatmaitan Z, Budding M, Steiglitz K, Arceci R, Arias IM. Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncology Research 4(8/9):359–365, 1992.

    PubMed  CAS  Google Scholar 

  34. Tsuruo T, Ida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733, 1982.

    PubMed  CAS  Google Scholar 

  35. Reymann A, Looft G, Woermann C, Dietel M, Erttmann R. Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCL Cancer Chemother Pharmacol 32:25–30, 1993.

    CAS  Google Scholar 

  36. Huet S, Chapey C, Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer 29A(10):1377–1383, 1993.

    PubMed  CAS  Google Scholar 

  37. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80(6):1528–1536, 1992.

    PubMed  CAS  Google Scholar 

  38. Jachez B, Boesch D, Grassberger MA, Loor F. Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. Anti-Cancer Drugs 4:223–229, 1993.

    PubMed  CAS  Google Scholar 

  39. Hyafil F, Vergely C, Du Bignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GY120918, an acridonecarbonxamide derivative. Cancer Res 53(19):4595–4602, 1993.

    PubMed  CAS  Google Scholar 

  40. Jaffrezou JP, Levade T, Chatelain P, Laurent G. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer 2-isopropyl-l-4-[3-N-dimethoxy-b-phenethyl)amino] propyloxy-benzenesulfonyl indolizine1. Cancer Res 52:6440–6446, 1992.

    PubMed  CAS  Google Scholar 

  41. Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst 86(9):688–694, 1994.

    PubMed  CAS  Google Scholar 

  42. Yang CH, Shen H, Horwitz SB. Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst 86(9):723–725, 1994.

    PubMed  CAS  Google Scholar 

  43. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 83(19):1386–1391, 1991.

    PubMed  CAS  Google Scholar 

  44. Efferth T, Volm M. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50:303–308, 1993.

    PubMed  CAS  Google Scholar 

  45. Petrini M, Mattii L, Valentini P, Sabbatini A, Grassi B, Grandi M. Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines. Ann Hematol 67:227–230, 1993.

    PubMed  CAS  Google Scholar 

  46. Lacayo N, Durán G, Sikic B. SDZ PSC 833 modulation of resistance to idarubicin in multidrug resistant (MDR) cell models. Proc Am Assoc Cancer Res 35:352, 1994.

    Google Scholar 

  47. Bittl A, Nap M, Jager W, Lathan B, Lang N. Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: a comparative study of three monoclonal antibodies, JSB-1, 219 and 265/F4, against different epitopes using frozen and paraffin tissue sections. Tumor Biol 14:155–166, 1993.

    CAS  Google Scholar 

  48. Herzog CE, Trepel JB, Mickely LA, Bates SE, Fojo AT. Various methods of analysis of mdr-Pglycoprotein in human colon cancer cell lines. J Natl Cancer Inst 84(9):711–716, 1992.

    PubMed  CAS  Google Scholar 

  49. Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of multidrug resistance by flourescent dyes. Cancer Res 51:4665–4670, 1991.

    PubMed  CAS  Google Scholar 

  50. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71(8):2454–2460, 1993.

    PubMed  CAS  Google Scholar 

  51. Vollrath V, Chiannale J, Gonzalez S, Duarte I, Andrade L, Ibanez L. Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions. Virchows Archiv B Cell Pathol 60:133–138, 1991.

    CAS  Google Scholar 

  52. Isshiki K, Nakao A, Ito M, Hamaguchi M, Takagi H. P-glycoprotein expression in hepatocellular carcinoma. J Surg Oncol 52:21–25, 1993.

    PubMed  CAS  Google Scholar 

  53. Huang C, We M, Xu G, Li D, Cheng H, Tu Z, Jiang H, Gu J. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262–263, 1992.

    PubMed  CAS  Google Scholar 

  54. Nishiyama K, Shirahama T, Yoshimura A, Sumizawa T, Furukawa T, Ichikawa-Haraguchi M, Akiyama S, Ohi Y. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas. Cancer 71(11):3611–3619, 1993.

    PubMed  CAS  Google Scholar 

  55. Haak HR, van Seters AP, Moolenaar AJ, Fluren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 29A(7):1036–1038, 1993.

    PubMed  CAS  Google Scholar 

  56. Ramel M, Van Den Bossche J, Buysse C, Van Meerbeeck J, Segers K, Vermeire P, Van Marck E. Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in nonneoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathology 167:5–8, 1992.

    Google Scholar 

  57. Pasman PC, Schouten HC. Multidrug resistance mediated by P-glycoprotein in haematol-ogical malignancies. Netherlands J Med 42:218–231, 1993.

    CAS  Google Scholar 

  58. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofmann J, Thaler J. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 85(21):1751–1758, 1993.

    PubMed  CAS  Google Scholar 

  59. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704, 1990.

    PubMed  CAS  Google Scholar 

  60. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614, 1991.

    PubMed  CAS  Google Scholar 

  61. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79(2):473–476, 1992.

    PubMed  CAS  Google Scholar 

  62. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr 1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586–592, 1991.

    PubMed  CAS  Google Scholar 

  63. Pirker R, Wallner J, Götzl M, et al. MDR1 RNA expression is an independent prognostic factor in acute myeloid leukemia. Blood 80(2):557–559, 1992.

    Google Scholar 

  64. Tiirikainen MI, Elonen E, Ruutu T, Jansson SE, Krusius T. Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 50:279–285, 1993.

    PubMed  CAS  Google Scholar 

  65. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77:50–53, 1991.

    PubMed  CAS  Google Scholar 

  66. Holmes JA, West RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 69:382–384, 1994.

    PubMed  CAS  Google Scholar 

  67. Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73(3):747–752, 1989.

    PubMed  CAS  Google Scholar 

  68. Ucci G, Petrini M, Riccardi A, Invernizzi R, Carulli G, Luoni R, Giordano M, Danova M. Expression of pl70 protein in multiple myeloma: a clinical study. Hematol Oncol 10:213–220, 1992.

    PubMed  CAS  Google Scholar 

  69. Cheng AL, Su IJ, Chem YC, Lee TC, Wang CH. Expression of P-glycoprotein and clutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol ll(l):109–115, 1993.

    Google Scholar 

  70. van der Zee AGJ, Hollema H, Suurmeyer A, Willense PHB, Krans M, Sluiter WJ, Aalders JG, de Vries EGE. P-glycoprotein (P-GP), glutathione S-transferase (GST) PI, C-ERB-B2, and P53: new prognostic factors in advanced stage ovarian cancer. Proc Am Soc Clin Oncol 13:256, 1994.

    Google Scholar 

  71. Lehnert M. Reversal of multidrug resistance in breast cancer: many more open questions than answers. Ann Oncol 4:11–13, 1993.

    PubMed  CAS  Google Scholar 

  72. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116, 1991.

    PubMed  CAS  Google Scholar 

  73. Chan HS, Koren CG, Thorner PS, Haddad VG, Giesbrecht E, Greenberg MD, Ling V, Gallie BL. Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin A (CSA). Proc Am Soc Clin Oncol 11:375, 1992.

    Google Scholar 

  74. Gascoyne R, Tolcher A, Van Iderstine E, Connors J. The prognostic relevance of P-glycoprotein expression in malignant lymphomas. Proc General Motors Cancer Res Foundation Intl Symp A7, 1993.

    Google Scholar 

  75. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl PK, Wick MR, Tsuruo T, Bloomfield OD. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768–3775, 1992.

    PubMed  CAS  Google Scholar 

  76. Moriyama M, Sugawara I, Hamada H, et al. Elevated expression of P-glycoprotein in kidney and urinary bladder cancers. Tohoku J Exp Med 164:191–201, 1991.

    PubMed  CAS  Google Scholar 

  77. Kelley DJ, Pavelic ZP, Gapany S, Gluckman JL. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 119:411–414, 1993.

    PubMed  CAS  Google Scholar 

  78. Levine EA, Holzmayer TA, Roninson IB, Das Gupta TK. MDR-expression in metastatic malignant melanoma. J Surg Res 54:621–624, 1993.

    PubMed  CAS  Google Scholar 

  79. Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F, Picci P, Boiocchi M. Expression of MDR1 and GST-p in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 3:63–69, 1991.

    Google Scholar 

  80. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 5(9):1452–1460, 1987.

    PubMed  CAS  Google Scholar 

  81. Holzmayer TA, Hilsenbeck S, Von Hoff D, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84(19):1486–1491, 1992.

    PubMed  CAS  Google Scholar 

  82. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787–791, 1990.

    PubMed  CAS  Google Scholar 

  83. Botti G, Chiappetta G, D’Aiuto G, De Angelis E, De Matteis A, Montella M, Picone A, Cascione F. PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An immunohistochemical, retrospective study. Tumori 79:214–218, 1993.

    PubMed  CAS  Google Scholar 

  84. Chevillard S, Vielh P, Pouillart P. Multidrug resistance gene expression is a predictive marker of response to neoadjuvant chemotherapy of breast cancer. Ann Oncol 5(S5):158, 1994.

    Google Scholar 

  85. Pozza F, Bevilacqua P, Cazzavillan MS, Gasparini G. P-glycoprotein expression (PGE) predicts chemoresistance (CR) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 12:65, 1993.

    Google Scholar 

  86. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 6:85–92, 1991.

    Google Scholar 

  87. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 18:239–242, 1986.

    PubMed  CAS  Google Scholar 

  88. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17–24, 1991.

    PubMed  CAS  Google Scholar 

  89. Salmon SE, Dalton WS, Grogan RM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44–50, 1991.

    PubMed  CAS  Google Scholar 

  90. Scheithauer W, Schenk T, Czejka M. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68:8–9, 1993.0

    PubMed  CAS  Google Scholar 

  91. Tolcher AW, Cowan KH, Solomon D, et al. A phase I study of paclitaxel (T) with R-verapamil (RV) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 13:139, 1994.

    Google Scholar 

  92. Scheulen ME, Niibler V, Kriegmair M, Lehmann M, Rathgeb W, Seeber S. Phase I study of I.V. dexniguldipine plus vinblastine. Proc Am Soc Clin Oncol 13:156, 1994.

    Google Scholar 

  93. Presant CA, Kennedy PS, Wiseman C, Gala K, Bouzaglou A, Wyres M, Naessig V. Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 9:355–357, 1986.

    PubMed  CAS  Google Scholar 

  94. Dalmark M, Pals H, Johnsen AH. Doxorubicin in combination with verapamil in advanced colorectal cancer: A phase II trial. Acta Oncol 30:23–26, 1991.

    PubMed  CAS  Google Scholar 

  95. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641–647, 1987.

    PubMed  CAS  Google Scholar 

  96. Ohi Y, Ohmori H, Shirahama T, Kawahara M, Matsumura Y, Tsushima T, Ohashi Y. Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother Pharmacol 30:S50–S54, 1992.

    PubMed  Google Scholar 

  97. Hendrick AM, Harris AL, Cantwell BMJ. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann Oncol 2:71–72, 1991.

    PubMed  CAS  Google Scholar 

  98. Mross K, Hamm K, Hossfeld DK. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 31:369–375, 1993.

    PubMed  CAS  Google Scholar 

  99. Mross K, Bohn C, Edler L, Jonat W, Queisser W, Heidemann E, Goebel M, Hossfeld DK. Randomized phase II study of single-agent epirubicin +/-verapamil in patients with advanced metastatic breast cancer. Ann Oncol 4(l):45–50, 1993.

    PubMed  CAS  Google Scholar 

  100. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatrie tumors. Cancer Res 49:1063–1066, 1989.

    PubMed  CAS  Google Scholar 

  101. Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB. Phase I and pharmaco-kinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168–1171, 1991.

    PubMed  CAS  Google Scholar 

  102. Wilson WH, Bates S, Kang YK, et al. Reversal of multidrug resistance (mdr-1) with R-verapamil and analysis of mdr-1 expression in patients with lymphoma refractory to EPOCH chemotherapy. Proc Am Assoc Cancer Res 34:212, 1993.

    Google Scholar 

  103. Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR Harris AL. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br J Cancer 65:267–270, 1992.

    PubMed  CAS  Google Scholar 

  104. van Kalken CK, van der Hoeven JJM, de Jong J, et al. Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27(6): 739–744, 1991.

    PubMed  Google Scholar 

  105. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G, Verweij J. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2:305–306, 1991.

    PubMed  CAS  Google Scholar 

  106. Warner E, Tobe S, Pei Y, Trachtenberg J, Skorecki K. Phase I trial of vinblastine (VBL) with oral cyclosporine A (CSA) as a multidrug resistance modifier in renal cell carcinoma. Proc Am Soc Clin Oncol 11:204, 1992.

    Google Scholar 

  107. Sonneveld P, Marie J. Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Am Assoc Cancer Res 35:358, 1994.

    Google Scholar 

  108. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642, 1992.

    PubMed  CAS  Google Scholar 

  109. Yahanda AM, Adler KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634, 1992.

    PubMed  CAS  Google Scholar 

  110. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting AST, Seynaeve C, Stoter G, Nooter K. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64:361–364, 1991.

    PubMed  CAS  Google Scholar 

  111. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12(4):835–842, 1994.

    PubMed  CAS  Google Scholar 

  112. Erlichman C, Moore M, Thiessen J, et al. Phase I Pharmacokinetic study of cyclosporin A combined with doxorubicin. Can Res 53:4837–4842, 1993.

    CAS  Google Scholar 

  113. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O’Brien SM, Ratain MJ. Modulation of vinblastine resistance with cyclosporine: A phase I study. Clin Pharmacol Therapeut 54(4):421–429, 1993.

    CAS  Google Scholar 

  114. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifer in acute leukemia. J Clin Oncol ll(9):1652–1660, 1993.

    Google Scholar 

  115. Yahanda AM, Adler KM, Fisher GA, et al. Phase I Trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1631, 1992.

    PubMed  CAS  Google Scholar 

  116. Fisher GA, Bartlett NL, Lum BL, Brophy NA, Durán M, Ehsan J, Halsey J, Sikic BI. Phase I trial of taxol (T) with high dose cyclosporine (CsA) as a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 13:144, 1994.

    Google Scholar 

  117. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811–1816, 1992.

    PubMed  CAS  Google Scholar 

  118. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J, Harris AL. ntermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28A:805–810, 1992.

    PubMed  CAS  Google Scholar 

  119. Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br J Cancer 66:833–839, 1992.

    PubMed  CAS  Google Scholar 

  120. Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 46:292–297, 1992.

    PubMed  CAS  Google Scholar 

  121. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol ll(12):2417–2426, 1993.

    Google Scholar 

  122. Isonishi S, Kirmani S, Kim S, Plaxe SC, Braly PS, McClay EF, Howell SB. Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. J Natl Cancer Inst 83(9):621–626, 1991.

    PubMed  CAS  Google Scholar 

  123. Budd GT, Bukowski RM, Lichtin A, Bauer L, Van Kirk P, Ganapathi R. Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. Invest New Drugs 11:75–79, 1993.

    PubMed  CAS  Google Scholar 

  124. Wishart GC, Bissett D, Paul J, et al. Quinidine resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomised trial. J Clin Oncol 9, in press.

    Google Scholar 

  125. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Bleehen NM. A phase I study fo intravenous SDZ PSC-833 in patients with advanced cancer. Ann Oncol 5(5):159, 1994.

    Google Scholar 

  126. Scheuten ME, Meusers P, Schröder J, Uppenkamp M, Skorzec M, Weimar C, Brittinger G, Seeber S. Effect of dexniguldipine (B935) on the efficacy of daunorubicin (DNR) plus high-dose cytosin-arabinoside (ara-C) in refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 12:308, 1993.

    Google Scholar 

  127. Catimel G, Sarkany M, Ardiet C, et al. Phase I trial of S 9788 in combination with Adriamycin as a new multidrug resistance reverser in solid tumors. Ann Oncol 5(5): 159, 1994.

    Google Scholar 

  128. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: a phase I/II study. Cancer 65:1895–1902, 1990.

    PubMed  CAS  Google Scholar 

  129. Kloke O, Osieka R. Interaction of cyclosporin A with antineoplastic agents. Klin Wochenschr 63:1081–1082, 1985

    PubMed  CAS  Google Scholar 

  130. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255–259, 1992.

    PubMed  CAS  Google Scholar 

  131. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837–4842, 1993.

    PubMed  CAS  Google Scholar 

  132. Bertrand Y, Capdeville R, Balduck N, Philippe N. Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. Am J Hematol 40:158–159, 1992.

    PubMed  CAS  Google Scholar 

  133. Durán GE, Gosland MP, Ho AL, Sikic BI. In vitro modulation of multidrug resistance (MDR) using human patient serum from EP-1: a phase I clinical trial of etoposide (VP-16) and SDZ PSC 833. Proc Am Assoc Cancer Res 35:351, 1994.

    Google Scholar 

  134. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor expiants. J Natl Cancer Inst 81:844–849, 1989.

    PubMed  CAS  Google Scholar 

  135. Thalhammer T, Veith CM, Gajzik L, Tanczos K, Swatonek H, Graf J. Selective inhibition of P-glycoprotein in liver by the non-immunosuppressive cyclosporin analog SDZ PSC 833. Ann Oncol 51(S5):157, 1994.

    Google Scholar 

  136. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Over-expression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357–361, 1994.

    PubMed  CAS  Google Scholar 

  137. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475–1479, 1993.

    PubMed  CAS  Google Scholar 

  138. Chen Y, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT. Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265(17):10073–10080, 1990.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. George A. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bert L. Lum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Branimir I. Sikic
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Southern California Cancer Center, USA

    F. M. Muggia

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fisher, G.A., Lum, B.L., Sikic, B.I. (1995). The reversal of multidrug resistance. In: Muggia, F.M. (eds) Concepts, Mechanisms, and New Targets for Chemotherapy. Cancer Treatment and Research, vol 78. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2007-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2007-8_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5829-9

  • Online ISBN: 978-1-4615-2007-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation